LINKING AUSTRALIAN & US CAPITAL MARKETS
OFFICES IN NEW YORK & AUSTRALIA
POWERED BY A
Consisting of highly skilled and dedicated investment bankers, company executives, entrepreneurs and industry experts.
We provide high quality and senior-level strategic advice to our clients, originating and executing transactions for future company growth to maximize shareholder value. We are committed to consistently meet and exceed our clients’ high expectations.
At Cove, we leverage our deep relationships with top-tier institutional investors to help companies raise funds, including equity, debt and hybrid capital.
Cove also functions in an IPO advisory role for the Australian (ASX) and US (NASDAQ) markets, and has the expertise to assist company growth through business development, strategic partnerships, enterprise agreements and M&A. We provide industry insights and market analysis to showcase our clients’ competitive advantage and market opportunity.
*Cove is AFSL licensed in Australia and is an affiliate of Trump Securities, a FINRA registered Broker Dealer in the United States (https://brokercheck.finra.org/)
THE COVE CAPITAL DIFFERENCE
Cove seeks new innovative technologies that shape the future of our global market.
Disruptive & IP-rich technology
Healthcare life sciences, biopharmaceuticals, & medical technology
HOW COVE CAPITAL
CAN HELP YOU GROW
STRUCTURING & VALUATION
SOME OF OUR GLOBAL CLIENTS
MEET COVE CAPITAL
Malcolm is a known leader in venture capital, private equity and corporate finance across Asia Pacific and is well recognized for building trusted, long standing partnerships. He achieves this through a commitment to delivering best practice advisory and consulting services to help his clients grow their businesses.
Pini Althaus is a commercial and technology entrepreneur with holdings in technology companies that he has founded and helped develop as both an angel investor and incubator. Pini has 25 years of public and private company executive experience, having directly raised over $200 million. Pini is best known for his business development acumen and for his ability in taking companies from concept to commercialization.
Mr Solitario is an experienced financial executive having commenced his career at Arthur Young (now Ernst & Young), Chartered Accountants in 1982. His experience since his early days as a Chartered Accountant spans across many industries having acted in senior management, company secretarial and directorship roles in organisations involved in environmental technology, automotive technology, telecommunications, film and television production, winemaking, primary production and in recent years biotechnology and medical technology.
Mr Solitario brings 30 years of considerable experience in the development of new and emerging technology, with a deep understanding of licensing and commercialisation of intellectual property. He has raised over A$150M in capital from private, public and government institutions, predominantly for the development of intellectual property.
Mr Solitario is a founding shareholder of Medibio Ltd, a company listed on the Australian Stock Exchange, pioneering the use of circadian biometrics as means to more objectively screen, diagnose, monitor and manage mental health conditions. Having incorporated Invatec Health Pty Ltd (predecessor of Medibio Ltd) in 2007, it now has significant operations in the United States and has collaborations with two of the most prestigious medical institutions in America being Johns Hopkins and Mayo Clinic, amongst others. In May 2018 Medibio received CE (Conformité Européenne) Marking certification for its first release technology product and platform.
Mr Solitario is also an affiliate partner of Cove Capital Pty Ltd with an extensive network of angel investors, venture capitalists, fund managers and stockbrokers. His focus in recent years has been to raise capital for the advancement of medical technology that has potential to make a positive impact in peoples lives. His focus in recent years has been to raise capital for the advancement of medical technology that has potential to make a positive impact in people’s lives.
Clive has over 30 years of experience across a broad spectrum of the global securities industry and commodity markets. He has worked for investment funds as a portfolio manager, advised in corporate strategy, capital raising, restructuring, refinancing and merger and acquisitions. Clive was instrumental in developing Canaccord Genuity Inc.’s Australian Mining Equity Sales and Research business globally. He was Head of Australian Institutional Equity Sales and Trading across North America for Prudential-Bache. Clive started and developed into number one – ranked, the Institutional Equity Derivative Sales & Trading Department for Ord Minnett Securities Inc (now JPMorgan) in Australia. Clive is a qualified Chartered Accountant with a BCom., CTA (University of Cape Town) and Corporate and Securities Law (RMIT).
DR. MATT MESNIK
Chief Medical Officer
Dr. Mesnik is an accomplished Healthcare Executive with 25 years of healthcare management experience. In Matthew’s most recent role, he was Chief Medical Officer of MinuteClinic, the pioneer and largest provider of retail-based health clinics in the US, prior to its acquisition by CVS, which is the second largest drug retailer in the US. During his time at MinuteClinic, it grew from 80 clinics to more than 550 clinics in 25 states with 300 physicians, and nearly 3 million annual patient visits.
CONTACT COVE CAPITAL
85 Broad Street, 28th Fl.
New York NY 10004
United States Of America
Tel: +1 212 739 0468